Searchable abstracts of presentations at key conferences in endocrinology

ea0032p10 | Adrenal cortex | ECE2013

First phase insulin secretion is impaired by aldosterone excess in primary aldosteronism

Fischer Evelyn , Adolf Christian , Pallauf Anna , Then Cornelia , Bidlingmaier Martin , Beuschlein Felix , Seissler Jochen , Reincke Martin

Context: Primary aldosteronism (PA) represents the most frequent cause of a curable secondary arterial hypertension. Conflicting data have been published regarding the effect of aldosterone excess on glucose and lipid metabolism.Objective: Our aim was to analyze insulin sensitivity and beta cell function in a cohort of PA patients. Prospective follow-up investigations were performed in a subgroup of patients before and after adrenalectomy to assess the m...

ea0041ep5 | Adrenal cortex (to include Cushing's) | ECE2016

Paradoxical worsening of lipid metabolism after successful treatment of primary aldosteronism

Adolf Christian , Asbach Evelyn , Dietz Anna , Hahner Stefanie , Quinkler Marcus , Rump Lars Christian , Bidlingmaier Martin , Treitl Marcus , Hallfeldt Klaus , Beuschlein Felix , Reincke Martin

Primary aldosteronism (PA) describes the most frequent cause of secondary arterial hypertension. Aldosterone itself represents a BP-independent cardiovascular risk factor associated with increased rates of morbidity and mortality. Recently a worsening of lipid metabolism after treatment has been described.Objective: Our aim was to analyse changes in lipid parameters according to treatment outcome in PA patients. Data of 215 consecutive PA patients with u...

ea0070aep1001 | Hot topics (including COVID-19) | ECE2020

Obstructive sleep apnea in primary aldosteronism is associated with cortisol cosecretion

Heinrich Daniel , Adolf Christian , Handgriff Laura , Schneider Holger , Nirschl Nina , Obster Elisabeth , Sturm Lisa , Wang Xiao , Bidlingmaier Martin , Wildgruber Moritz , Ladurner Roland , Beuschlein Felix , Reincke Martin

Background: Primary aldosteronism (PA) is a secondary form of arterial hypertension that – in case of unilateral disease – can be cured by surgery. Multiple studies have shown that PA patients are at higher risk to suffer from cardiovascular events and to develop metabolic diseases. Two thirds of patients with PA suffer from obstructive sleep apnea (OSA). A bi-directional, pathophysiological interplay between OSA and PA has been proposed, with focus on overnight ro...

ea0081oc13.2 | Oral Communications 13: Adrenal and Cardiovascular Endocrinology 2 | ECE2022

Early post-operative ACTH-stimulated aldosterone predicts long-term biochemical outcome in primary aldosteronism

Bruedgam Denise , Adolf Christian , Schneider Holger , Wegmann Verena , Schwarzlmueller Paul , Mueller Lisa , Holler Finn , Lechner Benjamin , Handgriff Laura , Ladurner Roland , Deniz Sinan , Williams Tracy Ann , Beuschlein Felix , Reincke Martin , Heinrich Daniel

Introduction: Primary aldosteronism (PA) is the most common surgically curable cause for endocrine hypertension. Patients with unilateral aldosterone-producing adenoma undergo adrenalectomy (ADX). Clinical and biochemical outcome is assessed 6-12 months after ADX according to PASO consensus. To reduce unnecessary follow-up visits and change in medication for diagnostic purposes for potentially cured patients after ADX, a prediction tool is needed. Previous research had shown g...

ea0070aep1002 | Hot topics (including COVID-19) | ECE2020

Intact endothelial epoxyeicosatrienoic acids pathway in primary aldosteronism – the route to new treatment strategies?

Fruehbuss Laura , Meng Yao , Sun Jing , Gonzalez Marques Jair , Koletzko Berthold , Mederos Y Schnitzler Michael , Gudermann Thomas , Beuschlein Felix , Ann Williams Tracy , Heinrich Daniel , Adolf Christian , Reincke Martin , Schneider Holger

Rationale: Endothelial dysfunction (ED) is a hallmark of primary aldosteronism and paves the way for subsequent atherosclerotic disease. Past research has confirmed that one factor involved in ED is disturbed nitric oxide (NO) signalling. Since defects in NO release alone cannot explain the whole effect, we set out to address the role of endothelial CYP-expoygenase products (epoxyeicosatrienoic acids, EETs) in aldosterone-mediated endothelial dysfunction.<p class="abstext"...

ea0094oc5.1 | Adrenal and Cardiovascular | SFEBES2023

Urine steroid metabolomics as a diagnostic tool in endocrine hypertension

Prete Alessandro , Abdi Lida , Suntornlohanakul Onnicha , Lang Katharina , Riancho Julien , Lazkani Aida , Larsen Casper K. , Gimenez-Roqueplo Anne-Paule , Pecori Alessio , Tetti Martina , Monticone Silvia , Muller Lisa M. , Adolf Christian , Timmers Henri J.L.M. , Hampson Stephanie , Eisenhofer Graeme , Ceccato Filippo , Beuschlein Felix , Kabat Marek , Bertherat Jerome , Dennedy Conall , Davies Eleanor , Deinum Jaap , Reincke Martin , Paolo Rossi Gian , Mulatero Paolo , Amar Laurence , Zennaro Maria-Christina , Sitch Alice J. , Tino Peter , Biehl Michael , Taylor Angela E. , Arlt Wiebke

Background: Hypertension affects more than 30% of the adult population worldwide and is a major cardiovascular risk factor. Identifying secondary causes of hypertension is key to offering targeted treatment and mitigating adverse health outcomes. We tested the performance of urine steroid metabolomics (USM), the computational analysis of 24-hour urine steroid metabolome data by machine learning, for diagnosing endocrine hypertension.<str...